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Neuroinflammation in the Peripheral Nerve:
Cause, Modulator, or Bystander in
Peripheral Neuropathies?
Rudolf Martini1 and Hugh Willison2
The role of innate and adaptive inflammation as a primary driver or modifier of neuropathy in premorbidly normal nerves, and
as a critical player in amplifying neuropathies of other known causes (e.g., genetic, metabolic) is incompletely understood and
under-researched, despite unmet clinical need. Also, cellular and humoral components of the adaptive and innate immune
system are substantial disease modifying agents in the context of neuropathies and, at least in some neuropathies, there is an
identified tight interrelationship between both compartments of the immune system. Additionally, the quadruple relationship
between Schwann cell, axon, macrophage, and endoneurial fibroblast, with their diverse membrane bound and soluble signal-
ling systems, forms a distinct focus for investigation in nerve diseases with inflammation secondary to Schwann cell mutations
and possibly others. Identification of key immunological effector pathways that amplify neuropathic features and associated
clinical symptomatology including pain should lead to realistic and timely possibilities for translatable therapeutic interven-
tions using existing immunomodulators, alongside the development of novel therapeutic targets.
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Introduction
The peripheral nervous system is organized in highly speci-alized anatomical and functional compartments in which
neuronal cell bodies in spinal cord or the dorsal root and
autonomic ganglia project the longest known mammalian
axons to specialized sensory receptors and muscle synapses.
Schwann cells directly encase axons throughout their length,
and within the broader nerve microenvironment many other
cell types including endothelial cells, pericytes, fibroblasts,
and macrophages provide support, surveillance, and likely still
undetected functions for proper structural and functional
maintenance of the peripheral nerve. The extraordinary physi-
ological complexity including maintenance and homeostasis
of this system in both normal and disease states involves
major input from the immune system. In this review, we con-
sider the disease states in which immunological activity acts
as a primary driver of pathological processes in autoimmune
states or modifies neuropathies of other causes. Although
there are some commonalities between the distinct disorders
(e. g., primary inflammation-mediated neuropathies vs. sec-
ondary inflammation of metabolically or genetically preper-
turbed nerves), there are also clear differences with regard of
the molecular, cellular, and subcellular pathomechanisms.
These pathomechanistic details may be important when
designing novel treatment approaches. In contrast, the advent
of sophisticated and targeted immunotherapies, as now widely
used in multiple sclerosis, could provide a chance for treating
inflammatory neuropathy of primary or secondary origin.
Innate and Adaptive Inflammation as a
Primary Driver of Neuropathy in Premorbidly
Normal Nerves
Guillain–Barre Syndromes
One of the clearest examples of a disease state in which
abnormal immune activation is the primary driver of a
destructive pathological process in nerve is the group of auto-
immune neuropathies referred to as the Guillain–Barre syn-
dromes (GBS; van den Berg et al., 2014). These acute
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disorders, reaching their clinical nadir within 4 weeks of
onset, are most usually driven by primary immune responses
to preceding infections that are inadvertently autoreactive and
target nerve plasma membrane components. In some cases,
molecular mimicry between microbial and nerve glycans has
been formally demonstrated to be the central component of
the immunopathological reaction (Willison, 2014). As the
primary immune response decays, or is actively suppressed by
restoration of immune tolerance, the acute neuroinflamma-
tory phase of the disorder resolves and regenerative pathways
take over. The clinical spectrum varies from a mild disorder,
in which ambulation is maintained, to a state of complete
paralysis, requiring mechanical ventilation. In both extremes,
good recovery may occur as remyelination of denuded axons
takes effect, provided the extent of irreversible axonal injury is
limited. While the driving immune factors in the acute
inflammatory phase are destructive, immune cell clearance of
myelin, and axonal debris resulting from direct injury and/or
Wallerian degeneration may be important for the tissue repair
process to be optimally effective (Cashman and Hoke, 2015;
Martini et al., 2013).
Historically, GBS was considered to be a single disorder;
however, it is now appreciated that within GBS, immune
attack may be directed at either myelin/Schwann cell mem-
brane components or axonal components. These subdivisions
are termed acute inflammatory demyelinating polyneuropathy
(AIDP) and acute motor axonal neuropathy (AMAN). The
immunopathology of AIDP and AMAN are quite distinct,
the former being characterized by macrophage-mediated mye-
lin stripping and the latter by primary axonal injury. A new
conceptualization of the dichotomization into AIDP and
AMAN is the evolving idea of the nodo-paranodopathy as a
more unifying categorization (Uncini and Kuwabara, 2015).
The definitive immunopathological study on AMAN was
conducted on spinal roots collected at autopsy by Griffin and
coworkers (1996). Degenerating motor fibers were observed
in the absence of demyelination, with extensive Wallerian
degeneration extending beyond the ventral root. Some motor
fibers had lengthening of the node of Ranvier accompanied
by condensation of the axonal cytoplasm. Infiltrating macro-
phages extended extensive processes into the periaxonal space
abutting the nodal and internodal axolemma and displacing
the adaxonal Schwann cell membrane and myelin sheath.
Intense IgG and complement C3d and C5b-9 (membrane
attack complex) deposits bound to the nodal and internodal
axolemma in the periaxonal space (Fig. 1).
Parallel studies conducted on human AMAN serum
samples around the time of these pathological observations
revealed autoantibodies to ganglioside components of axonal
membranes, notably GM1 and GD1a (Ho et al., 1999; Willi-
son and Yuki, 2002; Yuki et al., 1990). The anti-ganglioside
autoantibodies were found to also react with components of
Campylobacter jejuni lipo-oligosaccharide (LOS), this being
the major preceding infection in AMAN cases. From these
FIGURE 1: Schwann cell and axolemmal plasma membrane components within the nodal complex, including glycolipids and cell adhesion
molecules act as antigens for autoantibodies in acute and chronic autoimmune neuropathy phenotypes. Antibody binding activates the
classical complement cascade resulting in deposition of membrane attack complex (MAC). Calcium influx through MAC pores activates
calpain and injures vulnerable membranes whose function depends upon both structural integrity (maintained by glial–axonal adhesion
complexes) and ion homeostasis (maintained in part by Nav1.6 and Kv1.1 channels). Noncomplement fixing IgG4 subclass antibodies
may disrupt local architecture through blocking effects. Soluble complement products and other inflammatory factors recruit macro-
phages to the injury site.
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and related studies, it became clear that the immunological
cascade in the AMAN form of GBS started with enteric
infection by an appropriately glycosylated strain of C. jejuni.
This induced an anti-LOS antibody response that, as a conse-
quence of molecular mimicry, also bound to identical epi-
topes on neuronal gangliosides, resulting in the tissue
perturbation described above. From this example, it is thus
quite clear that normal nerve can be severely injured by
immune attack as a primary event. While the evidence for a
similar postinfectious immunological cascade in AIDP is less
well understood, it seems likely that ongoing research will
uncover closely analogous pathomechanisms.
Chronic Inflammatory Demyelinating
Polyneuropathy and Related Chronic Disorders
In contrast to the notion of GBS as a postinfectious self-
limiting disorder, chronic forms of peripheral nerve inflam-
mation have a less clear relationship to infectious precedents
but nevertheless appear due to primary autoimmune attack
on otherwise normal nerve. Chronic inflammatory demyeli-
nating polyneuropathy (CIDP) is the prototypic disorder,
manifested by motor and sensory deficits (Mathey et al.,
2015). Like GBS, it also invariably occurs in premorbidly
normal nerves, or evolves subacutely as an extension of unre-
solved GBS. Support for an autoimmune basis comes from
many threads of evidence, including biomarker studies, nerve
pathology, and responsiveness to immunotherapy; however,
the immunological triggers and subsequent cascade is poorly
understood and highly heterogeneous. Two curious antece-
dents merit mention. First, CIDP may occasionally occur fol-
lowing hematopoietic stem cell transplantation complicated
by graft versus host disease (Cocito et al., 2015) and second,
following anti-tumor necrosis factor-alpha (TNF-a) antibody
therapy as commonly used to treat rheumatoid arthritis
(Yagita et al., 2013). While the detailed underlying regulatory
mechanisms remain unclear, immune reprogramming and
dysfunction of networks maintaining tolerance are likely
involved.
Recent biomarkers studies in CIDP have identified
autoantibodies to cell adhesion molecules within the nodal
complex in a small number of CIDP cases, notably contactin-
1 and neurofascin (Lim et al., 2014; Ng et al., 2012; Querol
et al., 2013). The contactin/Caspr/NF155 complex is critical
for the formation and maintenance of paranodal junctions.
Some evidence suggests these antibodies may be directed
against mannose rich N-glycans within the extracellular
domain of contactin, and may interfere within the interaction
with NF155, thereby altering paranodal stability (Doppler
et al., 2015; Labasque et al., 2014). In this situation, a func-
tional blockade mediated by autoantibodies may be more
important than the induction of proinflammatory pathways.
Since in at least some of these cases, noncomplement fixing
IgG4 antibodies predominate, it will be important to dissect
out the downstream pathways leading to conduction failure,
as this will dictate the choice of therapies. What is clearly
emerging is that CIDP involves highly heterogeneous auto-
immune mechanisms, both clinically and immunopathologi-
cally (Beppu et al., 2015).
In other chronic inflammatory neuropathies, including
multifocal motor neuropathy and paraproteinemic neuropa-
thy, IgM antibodies to nerve glycolipids are frequently found,
the targets being the HNK-1 glycan on myelin-associated gly-
coprotein whose epitope is also shared by sulfated glucoronyl
paragloboside, and many gangliosides including GM1, GM2,
and the disialosyl-bearing gangliosides GD1b, GD3, GT1b,
and GQ1b. As these antibodies are generally of IgM class and
potent complement fixing molecules, it is generally believed
they act through promoting inflammation at their target
membranes; however, they may also exert deleterious cross-
linking or blocking effects, for example, trkC-mediated signal-
ling in dorsal root ganglion neurons (Kusunoki et al., 1999;
Takada et al., 2008).
The permanently elevated IgM anti-glycolipid antibod-
ies seen in these chronic disorders, in contrast to short-lived
IgG antibodies of the same specificities in the acute disorders,
may be secreted by long-lived plasma cells encoding anti-car-
bohydrate antibodies within the innate antibody repertoire.
Whether such B cells have encountered bacterial antigen-like
C. jejuni LOS, or expanded spontaneously, remains to be pro-
ven, but the anti-GM1 antibodies, at least, are certainly capa-
ble of binding LOS (Willison and Goodyear, 2013).
Spontaneous and Induced Animal Models in Which
Inflammation Is the Primary Driver of Neuropathy
Historically, the prototypic model of GBS has been the
induced rodent disorder, experimental allergic neuritis (EAN),
the peripheral nerve counterpart of experimental allergic
encephalomyelitis (Soliven, 2014). Many protocols have
evolved over the 50 years of its use in rats, mice, guinea pigs,
and rabbits and provided extensive information on immuno-
pathological mechanisms that may be relevant to specific fac-
ets of human disease (Gold et al., 2000; Maurer et al., 2002).
Active immunization with peripheral nerve components
including whole myelin or major myelin proteins P0, P2, and
PMP22, or with a wide range of glycolipids (e.g., GalC) and
gangliosides (e.g., GM1), adoptive transfer with myelin
antigen-specific T-cells, or passive immunization with specific
antibodies and antisera, alone or in combinations have all
yielded highly interesting models with unique immunological
and clinical features. Recent studies, for example, show criti-
cal regulatory roles for FoxP31 T-cells in disease severity of
several models of EAN (Meyer zu Horste et al., 2014). How
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closely these models map onto human disease is of great
interest and varies from case to case according to species and
strain, and immunization parameters. In some, such as sen-
sory ataxic neuropathy induced by anti-GD1b antibody in
the rabbit, the link is very clear as the presence of anti-GD1b
antibodies associates with ataxic neuropathy in man (Yuki
and Uncini, 2014). In others such as those induced by adop-
tive transfer of myelin-specific T-cells, the link is less clear
since expanded T-cell repertoires with myelin protein specific-
ity have not been widely identified in man, although recent
studies suggest they are present and modified by therapy
(Klehmet et al., 2015). What is evident is that a very wide
range of nerve-directed immunological stimuli can induce
both acute and chronic neuropathy which, when viewed as
models, serve the clinical investigative community well.
Two curious and tragic human immunization events
also inform the rodent modelling narrative. First, during the
era in which “ganglioside therapy” (i.e., injection of large
amount of purified brain gangliosides) for a range of miscella-
neous disorders was widespread, the incidence of GBS associ-
ated with anti-ganglioside antibodies was increased among
ganglioside therapy recipients relative to the general popula-
tion (Illa et al., 1995; Odaka et al., 2000). The prevailing
conclusion was that inadvertent immunization with intra-
muscularly injected gangliosides induced anti-ganglioside
antibody-mediated neuropathy. Another human immuniza-
tion event comprised an outbreak of autoimmune neuropathy
affecting abattoir workers exposed by inhalation to pig brain
aerosols liberated during animal carcass processing (Tracy and
Dyck, 2011). In essence, these workers received nasal immu-
nization with brain proteins and consequently developed
autoimmunity with amplified T- and B-cell responses to mul-
tiple brain and nerve antigens. One of the dominant antigens
was the voltage-gated potassium channel complex, a finding
which resonates with the sensory hyperexcitability symptoms
of pain and paresthesias experienced by the workers. These
observations made in humans with unwanted exposure to
putative autoantigens were subsequently taken full circle by
immunizing mice with the same pig brain aerosol and observ-
ing a similar immunological and clinical profile (Meeusen
et al., 2012). Both these examples serve to illustrate that
immunization of humans with nerve components can clearly
induce anti-nerve autoimmune responses, and thereby, injure
the target organ, in the same way that occurs in experimental
animals, as modeled in EAN.
In addition to induced models, a spontaneous auto-
immune polyneuropathy resembling CIDP occurs in non-
obese diabetic mice that lack the T-cell costimulatory
molecule B7-2 (Soliven, 2011). In these mice, the myelin
protein P0-specific CD41Th1 cell repertoire is expanded and
infiltrates the nerve where a demyelinating pathology ensues.
The model is widely used to explore basic mechanisms of tol-
erance and underlying regulatory T-cell repertoires (Meyer zu
Horste et al., 2014). Although pathologically resembling
CIDP, the mechanistic link to man is not established.
Antigen-Targeted Inflammation in Specialized
Nerve Compartments
As indicated above, one feature of human autoimmune neu-
ropathies is the exquisite targeting of very specific nerve com-
partments, fiber types or anatomical regions. Such selective
targeting is expressed clinically as a syndrome manifested by
purely motor, sensory, or autonomic features, or motor fea-
tures restricted to one anatomical site, while sparing others.
This is a certain testament to the highly complex organization
of peripheral nerves in terms of the distribution of molecular
components (capable of acting as antigens) that contribute to
its diverse structure and physiology, and the access that cellu-
lar and soluble immune factors have to those components.
For example, molecules within the nodal complex, when act-
ing as antigens, will attract autoinflammatory injury to that
site, as occurs with antibodies directed at the nodal adhesion
molecules such as neurofascin 186, contactin-associated pro-
tein 1, and contactin 1 (Querol et al., 2013). The clinical
phenotype in CIDP cases associated with anti-contactin 1
antibodies in one recent study includes sensory ataxia as the
predominant presenting clinical feature, suggesting that large
dorsal root ganglion neurons and their projecting myelinated
axons may be preferentially disrupted, despite the widespread
presence of contactin-1 in all myelinated fibers (Miura et al.,
2015). In mice, deficient in contactin-1 in which paranodal
dysfunction is present, ataxia is also a prominent feature,
although this may be due to aberrant cerebellar circuitry,
rather than loss of peripheral nerve afferent input (Boyle
et al., 2001). Conversely, anti-GM1 antibodies cause predom-
inantly weakness without sensory loss, through targeting axo-
lemmal GM1 in motor nerve fibers, despite the ubiquitous
presence of GM1 in all nerve fibers (Willison, 2014).
Another striking example of selective regional injury is seen in
the Miller Fisher syndrome, in which the anti-GQ1b antibodies
do not injure motor nerves in the limbs but preferentially affect
motor nerves innervating extraocular muscles, presumably
because GQ1b is enriched in this latter site (Chiba et al., 1997;
Liu et al., 2009). The immunopathological basis underlying
much of this diversity is unknown but reveals important princi-
ples, both clinically and fundamentally.
Inflammation and Neuropathic Pain
A frequent, nerve inflammation-related feature is neuropathic
pain due to aberrant activation of nociceptive fibers. Pain is a
major factor reducing quality of life and is frequently under-
recognized and poorly managed (Liu et al., 2015). While a
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traditional view would be that the major neuropathic pain
syndromes result from metabolic (e.g., diabetes, alcohol toxic-
ity), toxic (e.g., chemotherapy), or genetic (e.g., NaV channel
mutations, Fabry’s disease, amyloidosis) causes, the contribu-
tion of inflammatory mediators to these pathologies is
unclear, but may be substantial. Furthermore neuropathic
pain is also a major feature of more obviously inflammatory
neuropathies of diverse causes. Studies in animal models have
identified the release of proinflammatory cytokines (TNF-a,
IL-1a, IL-1b, and IL-6) from cells of both the innate and
adaptive immune system as well as from nonimmune cells
(Andratsch et al., 2009; Uceyler and Sommer, 2008). Particu-
larly the role of Schwann cells to express TNF-a during nerve
injury is worthwhile to emphasize as mediator for pain induc-
tion and maintenance, potentially by directly activating noci-
ceptors (Sorkin et al., 1997). Anti-inflammatory molecules,
such as erythropoietin and the competitive TNF-a inhibitor
etanercept are associated with recovery from neuropathic pain
states, underscoring the link between pain and inflammation
(Campana et al., 2006; Uceyler and Sommer, 2008).
The situation is complicated by experimental findings
that neuropathic stimuli are not only inducing painful inflam-
mation in the nerve but also lead to pain-related activation of
microglia in the spinal cord (Gao and Ji, 2010; Orita et al.,
2013; Walters, 2014). It is presently difficult to estimate the
individual contributions of inflammation in the peripheral
nervous system (PNS) versus in the central nervous system in
outcome. According to our view, the overarching problem with
pain and inflammation is that it is difficult to predict whether
in a particular nerve disorder inflammation is painful or not, as
exemplified by painful and painless CIDPs, painful and pain-
less diabetic neuropathies (DNs), and so forth. These issues are
underresearched and cannot be extended in this article.
Models for Inherited Peripheral Neuropathies
as Paradigm for Disease Amplification
by Inflammation
While the aforementioned neuropathies are primarily driven
by the immune system perturbing initially intact peripheral
nerves, inherited neuropathies are primarily caused by gene
mutations predominantly related to the nervous system. How-
ever, there is ample evidence that inflammation substantially
contributes to the disease outcome by amplification of the
genetically mediated disorders.
Regarding the genetical bases of the inherited neuropa-
thies, the three most common forms have been identified as
resulting from mutations in the Schwann cell-related myelin
genes for PMP22, Cx32 (GJB1), and P0 (MPZ) (Suter and
Snipes, 1995). Then, particularly the human genome project
substantially fueled the detection of further culprit genes
(Timmerman et al., 2014), comprising genes affecting cell
biological processes of glial cells and neurons at various levels
(Berger et al., 2006). Assorting the various disease types fol-
lows the Charcot–Marie–Tooth (CMT) classification, dividing
the disorders into demyelinating (CMT1) and axonal sub-
types (CMT2), but also considering clinical parameters such
as disease onset. Most forms show clinical commonalities
such as progressive distal muscle weakness, muscular atrophy,
and sensory dysfunction, mostly being downstream features of
axonal degeneration. Of particular relevance is that up to date
no therapies are available (Jerath and Shy, 2014).
Numerous genetically modified rodent CMT models of
have been generated (Fledrich et al., 2012). In models mimick-
ing CMT1A (most common), CMT1X (second most com-
mon), and CMT1B (third most common), achieved by mild
overexpression of peripheral myelin protein 22 (PMP22tg mice;
Huxley et al., 1998), deficiency for connexin 32 (Cx32def
mice; Anzini et al., 1997) and heterozygous deficiency for mye-
lin protein zero (P0het mice; Giese et al., 1992; Martini et al.,
1995), respectively, the mutations in these mice cause some
characteristic, dedifferentiation-related features typical for each
model (Klein et al., 2014). However, there are also remarkable
similarities among the distinct mutants, with inflammation
being a pathomechanistic commonality determining the ulti-
mate outcome of the disease (Groh et al., 2015b).
The aforementioned models share two important cyto-
kine pathways that are strongly related to nerve inflammation
and pathogenesis in inherited neuropathies: CCL2 and CSF-
1. Expressed by mutant Schwann cells, CCL2 has been iden-
tified as a component to attract and activate pathogenic mac-
rophages in peripheral nerves of CMT1 mutants by cross-
breeding experiments between CCL2-deficient mice and the
animal models (Fischer et al., 2008a; Groh et al., 2010; Kohl
et al., 2010a). However, the interpretation of the resulting
phenotypes was complicated in that only CMT1-models
being heterozygously deficient for CCL2 showed reduced
macrophage numbers and an alleviated phenotype, whereas
CMT1-models completely devoid of CCL2 failed to display
macrophage reduction and disease alleviation due to compen-
satory mechanisms implicating CSF-1 (Fischer et al., 2008a;
Groh et al., 2010; Kohl et al., 2010a). Interestingly, the
Schwann cell-intrinsic mechanism leading from myelin muta-
tion to CCL2 upregulation has been partially deciphered. An
important player within this pathway is the MEK-ERK sig-
nalling cascade, as pharmacological blockade of the cascade
inhibits CCL2 expression (Fischer et al., 2008b; Groh et al.,
2010; Kohl et al., 2010a). Interestingly, this cascade is also
activated after nerve injury (Harrisingh et al., 2004), reflect-
ing similarities between inherited neuropathies with Wallerian
degeneration (Martini et al., 2013). When the MEK-ERK
cascade is activated via a tamoxifen-inducible Raf-kinase
transgene in otherwise healthy myelinating Schwann cells,
Martini and Willison: Neuroinflammation in the Peripheral Nerve
April 2016 479
CCL2 expression is induced with inflammation-related down-
stream processes, like macrophage activation and demyelin-
ation (Napoli et al., 2012). Thus, the MEK-ERK cascade
clearly plays a pivotal role in the diseased peripheral nervous
system by linking Schwann cell pathology with detrimental
inflammation. Recent studies in an established rat model for
CMT1A have hypothesized that the basic culprit in the corre-
sponding disease is the disrupted maturation of the PMP22-
overexpressing Schwann cells due to an imbalance between
the PI3K-Akt and MEK-ERK pathways (Fledrich et al.,
2014). This view was supported by treating the mutants at an
early stage of disease with soluble neuregulin-1 tipping the
balance into the direction of PI3K-Akt, and thus, fostering
maturation and improved disease outcome (Fledrich et al.,
2014). Whether neuregulin-1 additionally indirectly attenu-
ated putatively detrimental macrophage activation by blocking
the MEK-ERK cascade would be interesting to investigate in
the future (Martini, 2014).
While PMP22 overexpression may directly lead to
impaired Schwann cell maturation/differentiation causing nerve
pathology, a recent study by Groh et al. (2015a) in Cx32def
mice proved that a CMT1-related myelin mutation alone is not
sufficient for Schwann cell immaturity/dedifferentiation and
nerve pathology. In mice heterozygously deficient for Cx32 and
showing a coexistence of Cx32wt and Cx32def Schwann cells
in one and the same nerve, pathogenic macrophage clusters
were only associated with Cx32def Schwann cells, reflecting a
target-directed behavior of nerve macrophages. It is plausible to
assume that under these conditions the pathogenic macrophage
clusters may be guided to their targets by CCL2, expressed by
the mutant Schwann cells (Groh et al., 2010, 2015a). Most
interestingly, when Cx32het, Cx32def, and P0het mice addi-
tionally lacked CSF-1, nerve pathology is robustly and con-
stantly ameliorated (Carenini et al., 2001; Groh et al., 2012,
2015a). Moreover, Schwann cells retained their differentiated,
myelinated phenotype although they displayed an activated
MEK-ERK cascade and increased levels of the downstream che-
mokine CCL2 (Groh et al., 2015a). The scenario is even more
complicated by the observation that the potent macrophage
activator CSF-1 is not expressed by Schwann cells, but by endo-
neurial fibroblasts (Groh et al., 2012; Martini et al., 2013).
This leads to the still unresolved question how fibroblasts
“sense” that the Schwann cells are mutant (Fig. 2).
In addition to the implication of innate immune cells,
there is also evidence for an involvement of the adaptive
immune system in models for inherited peripheral neuropa-
thies. In both P0het and Cx32def mice crossbreeding of these
myelin mutants with mice deficient in Rag1 (recombinase acti-
vating gene 1), lacking mature T- and B-lymphocytes, resulted
in a marked amelioration of the demyelinating and axono-
pathic phenotype and a reduction of macrophage numbers
(Kobsar et al., 2003; Schmid et al., 2000). Surprisingly, how-
ever, in PMP22tg mice the absence of lymphocytes does not
influence nerve pathology (Kohl et al., 2010b), while—as
FIGURE 2: Synoptic view of the interplay of cells and secreted molecules during secondary inflammation in CMT1 models. A not yet
identified primary activator (Activator 1) secreted from the mutant Schwann cells induces the endoneurial fibroblasts to express CSF-1
(Activator 2). CSF-1 will then activate the macrophages leading to myelin phagocytosis and Schwann cell dedifferentiation, implicating
not yet identified signalling molecule(s). Two other, possibly “fine-tuning” mechanisms have been identified in the form of CCL2 secre-
tion to guide the macrophages to their target (Schwann cells) and the endogenous antibodies binding to mutant Schwann cells and ena-
bling the macrophages to recognize their target, likely by Fc-receptors. Purple cell: mutant Schwann cell; brownish profile: myelinated
axon; yellow cell: macrophage; green cell: endoneurial fibroblast.
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discussed above—macrophages are crucial players in the
development of the pathology (Kohl et al., 2010a).
Which lymphocytes are responsible for the disease-
amplifying effect in P0het and Cx32def mice is not yet known.
In principle, B-lymphocytes might be interesting candidates as
antibodies produced by plasma cells and decorating nerve fibers
could function as potential recognition signals for phagocytiz-
ing macrophages as previously shown for Wallerian degenera-
tion (Vargas et al., 2010). Indeed, our recent findings
demonstrate that in peripheral nerves of P0het mice, endoge-
nous antibodies of IgG and IgM subtypes decorate endoneurial
tubes of peripheral nerves (Klein et al., 2015a). Crossbreeding
with JHD2/2 mice lacking B-cells and antibodies, lead to an
amelioration of disease similarly as described for P0het/RAG-1-
deficient mice. Interestingly, lack of evidence for complement
activation along the antibody-labeled fibres and increase of
nerve macrophages in antibody-reconstituted mice suggest an
interaction of nerve-bound antibodies with macrophages, most
probably via Fc-receptors (Klein et al., 2015a). Thus, endoge-
nous antibodies are excellent candidate molecules to link the
innate with the adaptive immune system in at least one model
of CMT1 neuropathies. However, this view does not exclude
the possibility that T-lymphocytes are also involved which
needs further investigations.
In summary, a picture emerged identifying a coordinated
interplay between components of both the innate and adaptive
immune system as amplifiers of the primarily genetically caused
neuropathies (Fig. 2). Within this scenario, a not yet identified
primary activator (Activator 1) secreted from the mutant
Schwann cells and inducing the endoneurial fibroblasts to
express CSF-1 (Activator 2) has to be postulated. CSF-1 will
then activate the macrophages leading to myelin phagocytosis
and Schwann cell dedifferentiation. As described above, 2 other,
possibly “fine-tuning” mechanisms have been identified in the
form of CCL2 secretion to guide the macrophages to their tar-
get and the endogenous antibodies binding to mutant Schwann
cells and enabling the macrophages to recognize their target,
likely by Fc-receptors and possibly others. Interestingly, Fc-
receptors have been identified to be upregulated by macro-
phages downstream of CSF-1 activation (Chitu and Stanley,
2006). There is hope that the deciphering of this interaction
and further investigations on inflammatory pathways in CMT-
models will provide opportunities for therapeutic options of the
so far untreatable disorders.
Potential Roles of Inflammation in Other
Primarily Immune-Unrelated Neuropathies
Diabetic Neuropathy
DNs are frequent and serious complications of diabetes melli-
tus types 1 and 2, preferentially affecting the longest axons of
the sensory, motor, and autonomous nervous system (Cashman
and Hoke, 2015; Hoke, 2012; Vincent et al., 2011). Remark-
ably, pathological leading features are axonal degeneration,
demyelination, and remyelination (Hoke, 2012; Vincent et al.,
2011). In the following, we will briefly focus on insights into
the inflammatory pathways of the length-dependent nerve dis-
orders, a topic that has very recently been reviewed comprehen-
sively by others (Cashman and Hoke, 2015).
The predominant symptoms with a significant, life
quality-reducing impact are sensory perturbations such as
pain and paresthesias or numbness, the latter of which can
lead to serious complications like ulcerations and amputa-
tions. Devastating consequences of the impaired autonomic
nervous system are—among others—reduced blood flow in
blood vessels which likely amplify the neuropathic features
(Cashman and Hoke, 2015; Vincent et al., 2011).
It is most likely that the full-blown image of DN com-
prises multiple and complicated pathomechanisms, implicat-
ing the polyol pathway, abnormal lipid metabolism, protein
glycosylation, radical-mediated damage, inflammation, and
the deficiency of neurotrophic factors (Cashman and Hoke,
2015; Vincent et al., 2011). The majority of these mecha-
nisms have partially been characterized in rodent models like
rats and mice, fed with the pancreatoxic compound streptozo-
tocin, a model best representing diabetes type 1 (Hoke,
2012). These models were particularly helpful in deciphering
some of the pathomechanisms, but studies in both nerve and
skin biopsies were also instrumental (Bekircan-Kurt et al.,
2014; Sommer, 2008).
One of the aforementioned aspects is the reduced glyce-
mic control, which may cause metabolic injury in neurons,
partially by means of mitochondrial damage via reactive oxy-
gen species. The link to inflammation is the generation of
advanced glycation end products (AGE), that is, organic com-
pounds like proteins, lipids, and nucleic acids that are nonen-
zymatically modified by reactive carbohydrate groups. These
can bind to a cognate cell surface receptor (RAGE; Cashman
and Hoke, 2015; Sandireddy et al., 2014; Vincent et al.,
2011), a pattern recognition receptor, likely playing a central
role in the inflammation-related pathogenic arm of DN. This
receptor is expressed in many different cells and tissues that
are potentially involved in immune reactions during DN,
including vessels, dermal endothelial cells, monocytes, macro-
phages, lymphocytes, peripheral epidermal axons, sural
axons, Schwann cells, dorsal root ganglia neurons, and others
(Bekircan-Kurt et al., 2014; Lin et al., 2009; Vincent et al.,
2011). Most importantly, the inflammation-related transcrip-
tion factor NF-kB is activated downstream of RAGE binding,
leading to the expression of a plethora of proinflammatory
cytokines activating inflammatory cascades with additional
detrimental effects, including oxidative stress (Sandireddy
et al., 2014; Yan et al., 1994; Yeh et al., 2001). The situation
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is complicated as the RAGE- NF-k B axis is also activated by
proinflammatory molecules and potentially by “accidental”
ligands (Lin et al., 2009), causing a potential vicious cycle of
disease amplification (Vincent et al., 2011). Potential down-
stream effectors of RAGE activation, such as TNF-a, have recently
been shown to be a disease promoting condition, as TNF-a recep-
tor blockade using a recombinant human TNF-a receptor-anti-
body fusion protein obviously alleviates streptozotocin-induced
DN in rats (Shi et al., 2013).
Although many experimental data exist, it is presently
difficult to get a clear picture of the impact of inflammation
in DN. It is plausible to assume that the many different cell
types expressing RAGE, the various different ligands, includ-
ing proinflammatory cytokines (Lin et al., 2009), cause a
pathogenic scenario of potentially tremendous complexity of
DN-related inflammation. This may even vary during disease
duration and progression. A scenario is emerging in which
DN is promoted by the direct inflammatory damage of neu-
ral cells or by impaired blood vessels or both. The overall
complexity of the inflammatory pathway may also explain
that some findings appear controversial and may depend on
variations in exact experimental design. For example, RAGE
inactivation has been reported to alleviate experimental DN
and promote PNS regeneration in some studies (Vincent
et al., 2011), but does not support slow axonal transport and
regeneration in others (Juranek et al., 2013). Moreover, even
the expression pattern of RAGE in nerve and skin biopsies
may vary, likely depending on the position of biopsy and/or
stage of disease (Bekircan-Kurt et al., 2014). In summary, it
is beyond doubt that more work is urgently needed to sys-
tematically unwrap the potentially important role of inflam-
mation in DN, as targeting inflammation may be an option
to mitigate DN. Applying novel sophisticated experimental
models (e.g., cell-specific and/or inducible RAGE mutants),
thoroughly defining experimental disease stages and using
standardized and translatable readout measures in the experi-
mental models are some of the most important improvements
for further studies (Hoke, 2012).
Importantly, there are additionally other types of neuro-
pathic disorders that can be typically seen in diabetic patients
and are associated with inflammation. For example, nerve
length-independent mononeuropathies and diabetic brachial or
lumbosacral plexoneuropathies (with nondiabetic derivatives)
are described (Dyck and Giannini, 1996; Dyck and Winde-
bank, 2002), but the underlying inflammatory processes could
so far not be molecularly characterized as in the length-
dependent DN, most likely due to lack of animal models.
Familial Amyloidotic Polyneuropathy
In contrast to DN, familial amyloidotic polyneuropathy
(FAP) is a rare neurological disorder. It is associated with the
deposition of amyloid fibrils in the endoneurium of the
peripheral nervous system and, when untreated, its prognosis
is fatal due to serious effects in vital organs (Sousa et al.,
2001b; Ueda and Ando, 2014). The disease is mostly associ-
ated with point mutations in the transthyretin (TTR) gene,
with a Val30Met substitution being the predominant cause
(Ueda and Ando, 2014). A link to inflammation has been
demonstrated by Yan et al. (2000) and Sousa et al. (2001b),
showing an interaction of amyloid fibrils with RAGE causing
downstream effects including NF-kB signalling and inflam-
mation, a surprising commonality with DN. TNF-a, IL-1b,
CSF-1 (M-CSF) have been identified as proinflammatory
downstream-components in FAP biopsies (Sousa et al.,
2001b). Unexpectedly, and in contrast to CMT neuropathy
and other models, the CSF-1 was reported to be found in
myelinated axons (Sousa et al., 2001a). A similarity to CMT
models is the observation that both in patients and transgenic
model mice the MEK-ERK cascade is activated within
Schwann cells as possible response to fibrillar deposition
(Monteiro et al., 2006). It is not known whether this leads to
a Schwann cell-borne CCL2 expression and macrophage acti-
vation as has been shown in CMT—and other transgenic
models of neuropathy (Napoli et al., 2012). In a recent study,
the group of Saraiva and colleagues report about the impact
of IL-1 during pathogenesis of FAP and show that the disease
can be ameliorated in a mouse model by the IL-1 antagonist
Anakinra (Goncalves et al., 2014, 2015). These combined
studies suggest that inflammation may play a modifying role
in the pathogenesis of FAP.
Targeting Inflammation as an Opportunity
to Make Diseases “Treatable”
Although nerve inflammation is generally known as causing dis-
ability and possibly pain in various peripheral nerve disorders,
the detailed negative impact of innate and adaptive inflamma-
tion on peripheral nerve structure, function, and regeneration is
under-researched and, therefore, poorly understood. There is
particular need for novel approaches targeting particular com-
partments of the immune system. Concerning the primary
inflammatory disorders, like CIDP, a recently initiated clinical
trial using modern immune modulators, like fingolimod
(FTY720), might be promising (Melzer and Meuth, 2014).
Current treatment for these conditions is limited to nonspecific
immunotherapies such as corticosteroids, broadly acting immu-
nosuppressants like azathiaprine and methotrexate, and intrave-
nous immunoglobulin and plasma exchange, both of which
have pleiotropic immune-modulating effects. The advent of
highly targeted immunotherapies, as now widely used in multi-
ple sclerosis, should provide further impetus for clinical trials in
inflammatory neuropathy (Nobile-Orazio and Gallia, 2013).
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As for the models for inherited neuropathies, the inflam-
matory disease pathway has been systematically investigated,
some specific options emerge which might be realistic to fol-
low. Beforehand, it has to be approved whether the situations
seen in the rodents faithfully reflect the situations in man.
Indeed, there are some observations supporting the view
that in human patients similar processes occur as in the mouse
models, especially in children with CMT1. Analogous to the
mouse models, myelin-laden foamy macrophages within the
endoneurial space can occasionally be detected by electron
microscopy (Crawford and Griffin, 1991). In addition, MHC
class II positive macrophages can often be found integrated
into onion bulb formations (Stoll et al., 1998). Even more
striking similarities between diseased nerves in animal models
and human biopsies have recently been reported: by the com-
bination of electron microscopy with immunohistochemical
approaches not only the presence of myelin-laden macrophages
was detected in both species, but, as a pathogenetically important
detail, also contacts of macrophages with fibroblasts expressing
CSF-1 have been found as commonality between biopsies of
CMT1 patients and nerves from the corresponding mouse mod-
els (Groh et al., 2012). These findings suggest that similar low-
grade inflammatory reactions might occur in the peripheral
nerves of CMT1 patients, especially early in pathogenesis. Taken
this as a base, it would now be interesting to investigate such
issues also in acquired neuropathies (NPs). A caveat might, how-
ever, be that (1) animal models for acquired neuropathies may
not always be faithful recapitulators of human disease and (2)
interrogating human peripheral nerve through tests such as sural
nerve biopsies are often not available, or yield insufficient tempo-
ral and spatial information to be of high value. However, these
could be partially replaced by the less invasive skin biopsies
(Nolano et al., 2015) to investigate a potential involvement of
macrophages in a respective NP.
A possible approach to inhibit or attenuate the mecha-
nisms related to inflammation have been identified in the
genetic mouse models using MEK-ERK cascade blockers
(Fischer et al., 2008b; Groh et al., 2010; Kohl et al., 2010a).
Although the effects in the genetic models was substantial, this
or related strategies are rather of academic value in CMTmod-
els rather than a realistic option in the nonfatal inherited neuro-
pathies, as the MEK-ERK pathway is pleiotropically involved
in a variety of cell biological processes and thus side effects have
to be expected by long term inhibition of this pathway. There-
fore, it is understandable that this strategy is only considerable
for severe malignancies (Rusconi et al., 2012).
Another direction for an immune-modulatory treatment
approach might emerge by interfering with the CSF-1-CSF-
1R axis, based on the robust and persistent amelioration of
neuropathy by CSF-1 deficiency in different CMT1 mouse
models (Carenini et al., 2001; Groh et al., 2012). A corre-
sponding pharmacological analog might be silencing the
CSF-1-CSF-1R axis by using appropriate inhibitors (Elmore
et al., 2014). Recently, a corresponding approach indeed led
to substantially improved histopathological, physiological, and
clinical features in two mouse models of inherited peripheral
neuropathies (Klein et al., in press).
Regarding DN, the RAGE-NF-kB axis leading to TNF-
a, IL-1b, and CCL2 expression, would theoretically be a pos-
sible target for amelioration of inflammation, neuropathic fea-
tures, and possibly pain. Surprisingly, treatment algorithms
for diabetic pain do obviously not consider anti-inflammatory
drugs (Vincent et al., 2011), although TNF-a can function
as mediator of neuropathic pain (Uceyler and Sommer,
2008). As RAGE is also expressed on endothelial cells, use of
anti-inflammatory drugs could theoretically also improve the
vascular complications as exemplified in treating diabetic rats
with erythropoietin (Vincent et al., 2011). Possibly future
experiments will show whether the many immune modulators
recently developed for treating multiple sclerosis might be
helpful for ameliorating one of the most common forms of
neuropathy, DN.
As an inflammation-related commonality between DN and
FAP, the RAGE-NF-kB axis would, theoretically, also be a target
for treatment. However, immunotherapies appear presently not
to play a predominant role in trying to treat FAP in the clinics.
Rather, the highly invasive liver transplantation is a therapeutic
option for patients below the age of 60 and inflammation unre-
lated drugs, like stabilizers of TTR tetramers (tafamidis and
diflunisal) and potentially gene-therapeutic approaches are novel,
noninvasive alternatives for liver transplantation (Adams et al.,
2014; Scott, 2014; Sekijima, 2014; Ueda and Ando, 2014).
Synopsis
In this article, we provide an overview of what is known
about the pathogenic impact of inflammation in peripheral
neuropathies. Along these lines, we discriminated neuropa-
thies primarily caused by the immune system (GBS, CIDP)
versus others in which secondary inflammation emerges as a
result of genetic abnormalities (CMTs) or impaired metabo-
lism (DN, FAP). Comparing these two major categories, it
appeared that there are inflammation-related commonalities,
but also clear differences between them. For instance, in
AMAN and CMTs, at first glance, macrophages appear to be
similar promoters of nerve damage when superficially viewed.
Upon detailed inspection, in AMAN macrophages slip into
nodes of Ranvier and precisely or even exclusively cause
axon damage, followed by features comparable of Wallerian
degeneration (Griffin et al., 1996). In CMT models, macro-
phages predominantly associate with the abaxonal aspect of
the mutant Schwann cells, lead to juxtaparanodal alterations
(Groh et al., 2012) and, in addition to myelin disruption,
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they promote a CSF-1-dependent dedifferentiation pathway of
Schwann cells which might be, secondarily, detrimental to
axons (Groh et al., 2015a). As this scenario appears to be more
related to CSF-1-dependent tumor-associated macrophages
that drive proliferation and dedifferentiation of mutant (tumor)
cells (Mantovani and Sica, 2010) than to macrophage-related
processes going on in GBS/AMAN, it is a tempting to speculate
that pathogenic mechanism within the nerve can strongly vary
among the different nerve disorders but can show clear
commonalities with disorders not at all related to the nervous
system (e.g., cancer). Another issue concerns the role of anti-
bodies. Antibodies specific to nodal, internodal, and presynap-
tic glycolipids but also against proteins belonging to the
nodal complex may either act as epitope-blocking agents and/or
fix complement that lead to cellular damage. Based on a
novel study, in the CMTs, endogenous antibodies also play a
mild, pathogenic role possibly activating macrophages via
Fc-receptors, as it is similarly observed in Wallerian degenera-
tion (Klein et al., 2015a; Vargas et al., 2010). However, there is
lack of evidence for an involvement of complement (Klein
et al., 2015a).
Taking into consideration that it is likely that upon
closer analysis of neuroinflammatory processes both common-
alities but also clear differences will emerge, it is pivotal to
thoroughly decipher the pathogenic impact of immune cells
very precisely. This could lead to the fortunate situation that
pathogenic commonalities to disorders will emerge for which
treatment approaches are already available.
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